The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Olympus Biotech Corporation
ClinicalTrials.gov Identifier:
NCT01217463
First received: October 7, 2010
Last updated: August 4, 2014
Last verified: August 2014

October 7, 2010
August 4, 2014
November 2010
March 2012   (final data collection date for primary outcome measure)
Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Wound closure is defined as 100% reepithelialization of the target DFU, without exudate.
To demonstrate a superior wound closure rate of diabetic foot ulcers (DFUs) of neuropathic topical daily application of trafermin 0.01% spray compared with placebo, in addition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
closure is defined as 100% reepithelialization of the target DFU, without drainage.
Complete list of historical versions of study NCT01217463 on ClinicalTrials.gov Archive Site
Relative Wound Area Regression of 40% or More at 6 Week [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
The incidence of wound area regression of at least 40% at week 6 was considered as an important exploratory secondary efficacy variable. The wound area regression was calculated as percentage change from inclusion at week 6 using centralized wound area data.
  • To determine the time to reach complete wound closure [ Designated as safety issue: No ]
  • To determine absolute and relative wound area regression and wound edge migration based on planimetry tracing [ Designated as safety issue: No ]
  • To determine the occurrence rate of clinical infection on the target DFU [ Designated as safety issue: No ]
  • To evaluate the safety of trafermin 0.01% spray [ Designated as safety issue: Yes ]
  • To determine the rate of amputations on the target DFU [ Designated as safety issue: No ]
  • To determine the maintenance of wound closure/time to re-opening up to 3 months after observed reepithelialization [ Designated as safety issue: No ]
  • To determine DFU new occurrence/recurrence up to 12 months [ Designated as safety issue: No ]
  • To assess high sensitivity C-Reactive Protein (hs CRP) level variations [ Designated as safety issue: No ]
  • To explore biomarkers from target wound fluid (selected centers only) [ Designated as safety issue: No ]
  • To explore the correlation of absolute and relative wound area regression and wound edge migration based on photography in comparison with planimetry tracing [ Designated as safety issue: No ]
  • To determine the frequency of local mechanical or surgical procedures [ Designated as safety issue: No ]
Not Provided
Not Provided
 
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment With Trafermin 0.01% Spray in Patients With Diabetic Foot Ulcer of Neuropathic Origin

Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan). Trafermin 0.01% cutaneous spray product kit consisting of a glass bottle containing lyophilized trafermin, a glass bottle with solvent for solution and a spray part to fit the glass bottle after reconstitution of the final product.

The investigators conduct a multinational, randomized, double-blind, placebo controlled, parallel-group, multicentre study consisting of a placebo run-in phase (2w), a treatment phase (max. 12w) and a follow-up phase (3mo+6mo). The primary objective of the study is to demonstrate a superior wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin after 12 weeks topical daily application of trafermin 0.01% spray compared with placebo, in addition to best local care (off-loading, dressings). Approximately 210 patients will be randomized and it is planned that this study will be conducted at approximately 30 investigational sites in an estimated 4 countries in Europe (Czech Republic,France,Hungary,Italy,).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetic Foot Ulcer of Neuropathic Origin
Drug: Trafermin 0.01% spray
For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
  • Active Comparator: Trafermin 0.01% spray
    Intervention: Drug: Trafermin 0.01% spray
  • Placebo Comparator: Matching placebo spray
    Intervention: Drug: Trafermin 0.01% spray
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
201
February 2013
March 2012   (final data collection date for primary outcome measure)

Selection Criteria

Patients who fulfill all of the following criteria (and none of the exclusion criteria described below) are eligible to enter the placebo run-in phase of the study:

  1. Provide written informed consent to participate.
  2. Male or female patients age 18 years or older.
  3. Type 1 or 2 diabetes.
  4. A single full-thickness DFU that has been present for at least 2 weeks.
  5. DFU wound surface area below or equal 34 cm2 on the target foot.
  6. No exposure of bone in the target DFU.
  7. Neuropathy confirmed by loss of protective sensation to monofilament test (Semmes-Weinstein 5.07 monofilament).
  8. No predominant ischemia requiring further exploration or treatment, and confirmed by either:

    • ABPI on the target leg ( >0.9;below or equal 1.3) or if ABPI is >1.3 or is not assessable,TBPI on target foot above or equal 0.7, OR
    • ABPI on target leg (above or equal 0.7;below or equal 0.9) or if ABPI is >1.3 or is not assessable, TBPI on target foot <0.7, AND a toe blood pressure >40 mmHg

Inclusion Criteria

Patients who fulfill all of the following criteria are eligible for randomization:

  1. All of the selection criteria and none of the exclusion criteria are met.
  2. Completed the 2-week placebo run-in period during which they were compliant to off-loading and to daily application of placebo spray, without major protocol violation. Compliance with the placebo run-in treatment regimen must be "excellent" or "acceptable"
  3. Glycosylated hemoglobin (HbA1c) below or equal 10% (from a blood sample taken during the placebo run-in period).
  4. Non-infected target foot DFU of confirmed neuropathic origin with:

    • ABPI on the target leg (>0.9;below or equal 1.3) or if ABPI is >1.3 or is not assessable,TBPI on target foot above or equal 0.7, OR
    • ABPI on target leg (above or equal 0.7;below or equal 0.9) or if ABPI is >1.3 or is not assessable, TBPI on target foot <0.7, AND a toe blood pressure >40 mmHg
  5. Target DFU appropriately debrided (<10% black and at least 50% of red/pink on a colorimetric scale)
  6. Target DFU of grade A1 or A2 on the University of Texas Wound Classification System or of Grade 1 or 2 of the Wagner classification
  7. DFU surface area above or equal 0.9 cm2 and below or equal 20 cm2 confirmed by the investigator's measurement, and its surface area not decreased by more than 40% compared to the selection value.

Exclusion Criteria

Patients who fulfill any of the following criteria are not eligible to be enrolled in the study:

  1. Active Charcot foot, or inactive Charcot foot, if the target DFU cannot be properly offloaded.
  2. Ulcers of non-neuropathic origin (e.g., rheumatoid, radiation-related, vasculitis-related ulcers).
  3. Presence of any foot ulcer (whether or not on the target foot) for which local or systemic antibiotic treatment is required.
  4. Evidence of skin cancer within or adjacent to the target ulcer.
  5. Any infected ulcers, defined as any problem such as (but not limited to) cellulitis, osteomyelitis, gangrene, or deep tissue infection requiring local or systemic antibiotic therapy.
  6. Another wound on the same foot as the target DFU. (i.e. Patients with another wound on the same limb as the target DFU are eligible for the study provided the concomitant wound is not infected and is above the ankle of the target foot).
  7. Any known active malignancy that requires general, local, surgical or radiation therapy either ongoing or within the previous 6 months; or patients whose treatment has been suspended for compassionate reasons, or who are not considered as cured from any malignancy.
  8. Morbid obesity, defined as body mass index (BMI) above or equal 45kg/m2.
  9. Clinically significant medical conditions, in the investigator's opinion, that could impair wound healing (e.g. hepatic impairment, immunocompromised patients).
  10. Severe renal failure, defined as requirement for hemodialysis or peritoneal dialysis.
  11. Females who are pregnant or breastfeeding, or who are of childbearing potential and not practicing a medically approved method of contraception.
  12. Concomitant treatment with high dose oral or parenteral corticosteroids, defined as a daily dose of at least 7.5 mg prednisone or equivalent.
  13. Participation in another clinical study within the previous 3 months.
  14. Current participation in another clinical study with any drug or device.
  15. History of drug or alcohol abuse within the previous year.
  16. Concurrent severe psychiatric disease (including severe depressive disorder).
  17. Known intolerance to the IMP or to any of its excipients.
  18. Known to be uncooperative or noncompliant.
  19. Outpatients who are unable to comply with the requirement for daily spray application at home (either application by a family member or by a visiting nurse).
  20. Any other condition which, in the opinion of the investigator, would render the patient unsuitable for the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   France,   Hungary,   Italy
 
NCT01217463
TFM-CL3-001, 2010-021014-33
Yes
Olympus Biotech Corporation
Olympus Biotech Corporation
Not Provided
Study Director: Jean-Charles Kerihuel, MD VERTICAL
Study Chair: Luc Téot, MD Montpellier University Hospital
Olympus Biotech Corporation
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP